Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 4, 2014, Pages 385-406

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CORTICOSTEROID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE;

AGE; AUTOIMMUNE HEPATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ELASTOGRAPHY; ENZYME ACTIVATION; ETHNICITY; EXTRACELLULAR MATRIX; HEPATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MORTALITY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

ANIMALS; DISEASE PROGRESSION; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 84892883803     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12592     Document Type: Review

References (272)

1. Manns MP, Czaja AJ, Gorham JD, et al,. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
2. Gleeson D, Heneghan MA,. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
3. Cook GC, Mulligan R, Sherlock S,. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.
4. Soloway RD, Summerskill WH, Baggenstoss AH, et al,. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
5. Murray-Lyon IM, Stern RB, Williams R,. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.
6. Schvarcz R, Glaumann H, Weiland O,. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993; 18: 15-23.
7. Roberts SK, Therneau TM, Czaja AJ,. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
8. Kanzler S, Lohr H, Gerken G, et al,. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001; 39: 44-8.
9. Floreani A, Niro G, Rosa Rizzotto E, et al,. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006; 24: 1051-7.
10. Seo S, Toutounjian R, Conrad A, et al,. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008; 23: 1410-4.
11. Hoeroldt B, McFarlane E, Dube A, et al,. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-9.
12. Ngu JH, Gearry RB, Frampton CM, et al,. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 2013; 57: 2399-406.
13. Mistilis SP, Skyring AP, Blackburn CR,. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival. Australas Ann Med 1968; 17: 214-23.
14. Davis GL, Czaja AJ, Ludwig J,. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 1222-7.
15. Czaja AJ, Manns MP,. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.
16. Czaja AJ,. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012; 57: 1996-2010.
17. Czaja AJ,. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013; 38: 343-64.
18. Czaja AJ,. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51: 161-7.
19. Manns MP, Woynarowski M, Kreisel W, et al,. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
20. Czaja AJ, Carpenter HA,. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819-25.
21. Inductivo-Yu I, Adams A, Gish RG, et al,. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802.
22. Hennes EM, Oo YH, Schramm C, et al,. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
23. Hlivko JT, Shiffman ML, Stravitz RT, et al,. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-40.
24. Wolf DC, Bojito L, Facciuto M, et al,. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009; 54: 2519-22.
25. Sharzehi K, Huang MA, Schreibman IR, et al,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588-92.
26. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al,. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34: 335-43.
27. Zachou K, Gatselis N, Papadamou G, et al,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011; 55: 636-46.
28. Mistilis SP, Vickers CR, Darroch MH, et al,. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985; 143: 463-5.
29. Hyams JS, Ballow M, Leichtner AM,. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-3.
30. Sherman KE, Narkewicz M, Pinto PC,. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
31. Jackson LD, Song E,. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-61.
32. Van Thiel DH, Wright H, Carroll P, et al,. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-6.
33. Alvarez F, Ciocca M, Canero-Velasco C, et al,. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 222-7.
34. Debray D, Maggiore G, Girardet JP, et al,. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135: 111-4.
35. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al,. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-7.
36. Hurtova M, Duclos-Vallee JC, Johanet C, et al,. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl 2001; 7: 556-8.
37. Aqel BA, Machicao V, Rosser B, et al,. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9.
38. Larsen FS, Vainer B, Eefsen M, et al,. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-6.
39. Tannous MM, Cheng J, Muniyappa K, et al,. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011; 34: 405-7.
40. Dufour JF, DeLellis R, Kaplan MM,. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981-5.
41. Cotler SJ, Jakate S, Jensen DM,. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001; 32: 428-30.
42. Czaja AJ, Carpenter HA,. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-52.
43. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al,. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 547-51.
44. Herold KC, Hagopian W, Auger JA, et al,. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-8.
45. Bresson D, Togher L, Rodrigo E, et al,. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116: 1371-81.
46. Burak KW, Swain MG, Santodomino-Garzon T, et al,. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013; 27: 273-80.
47. Weiler-Normann C, Schramm C, Quaas A, et al,. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58: 529-34.
48. Dhirapong A, Yang GX, Nadler S, et al,. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013; 57: 708-15.
49. Longhi MS, Meda F, Wang P, et al,. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008; 47: 581-91.
50. Lapierre P, Beland K, Yang R, et al,. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 2013; 57: 217-27.
51. Blumenfeld HJ, Tohn R, Haeryfar SM, et al,. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol 2011; 166: 121-33.
52. Czaja AJ,. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011; 17: 3120-40.
53. Czaja AJ,. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets 2012; 11: 351-63.
54. Wang KK, Czaja AJ,. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 1988; 8: 1679-83.
55. Park SZ, Nagorney DM, Czaja AJ,. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 1944-8.
56. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008; 103: 1944-51.
57. Yeoman AD, Al-Chalabi T, Karani JB, et al,. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008; 48: 863-70.
58. Ghiassi-Nejad Z, Friedman SL,. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol 2008; 2: 803-16.
59. Cohen-Naftaly M, Friedman SL,. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4: 391-417.
60. Friedman SL, Sheppard D, Duffield JS, et al,. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013; 5: 167sr1.
61. Baggenstoss AH, Soloway RD, Summerskill WH, et al,. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972; 3: 183-98.
62. Schalm SW, Korman MG, Summerskill WH, et al,. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977; 22: 973-80.
63. Wanless IR, Nakashima E, Sherman M,. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000; 124: 1599-607.
64. Wanless IR,. Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis. J Clin Gastroenterol 2001; 32: 371-2.
65. Desmet VJ, Roskams T,. Reversal of cirrhosis: evidence-based medicine? Gastroenterology 2003; 125: 629-30.
66. Soloway RD, Baggenstoss AH, Schoenfield LJ, et al,. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971; 16: 1082-6.
67. Abdi W, Millan JC, Mezey E,. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1979; 139: 667-9.
68. Theodossi A, Skene AM, Portmann B, et al,. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology 1980; 79: 232-41.
69. Maharaj B, Maharaj RJ, Leary WP, et al,. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.
70. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
71. Colloredo G, Guido M, Sonzogni A, et al,. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
72. Zimmermann H, Reichen J, Zimmermann A, et al,. Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Gastroenterology 1992; 103: 579-89.
73. Dunn MA, Cheever AW, Paglia LM, et al,. Reversal of advanced liver fibrosis in rabbits with Schistosomiasis japonica. Am J Trop Med Hyg 1994; 50: 499-505.
74. Powell LW, Kerr JF,. Reversal of "cirrhosis" in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med 1970; 19: 54-7.
75. Falkmer S, Samuelson G, Sjolin S,. Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease. Pediatrics 1970; 45: 260-8.
76. Soyer MT, Ceballos R, Aldrete JS,. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery 1976; 79: 601-4.
77. Kaplan MM, DeLellis RA, Wolfe HJ,. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997; 126: 682-8.
78. Sobesky R, Mathurin P, Charlotte F, et al,. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378-86.
79. Poynard T, McHutchison J, Davis GL, et al,. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-7.
80. Hammel P, Couvelard A, O'Toole D, et al,. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344: 418-23.
81. Kweon YO, Goodman ZD, Dienstag JL, et al,. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35: 749-55.
82. Muretto P, Angelucci E, Lucarelli G,. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136: 667-72.
83. Abergel A, Darcha C, Chevallier M, et al,. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 2004; 16: 1219-27.
84. Mallet V, Gilgenkrantz H, Serpaggi J, et al,. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
85. Bonis PA, Friedman SL, Kaplan MM,. Is liver fibrosis reversible? N Engl J Med 2001; 344: 452-4.
86. Arthur MJ,. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 1525-8.
87. Friedman SL, Bansal MB,. Reversal of hepatic fibrosis-fact or fantasy? Hepatology 2006; 43: S82-8.
88. Friedman SL,. Fibrogenic cell reversion underlies fibrosis regression in liver. Proc Natl Acad Sci USA 2012; 109: 9230-1.
89. Czaja AJ,. Hepatic inflammation and progressive hepatic fibrosis in chronic liver disease. World J Gastroenterol; in press.
90. Knodell RG, Ishak KG, Black WC, et al,. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
91. Czaja AJ, Carpenter HA,. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004; 39: 1631-8.
92. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
93. Czaja AJ,. Drug choices in autoimmune hepatitis: part A-steroids. Expert Rev Gastroenterol Hepatol 2012; 6: 603-15.
94. Devlin SM, Swain MG, Urbanski SJ, et al,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-6.
95. Czaja AJ,. Drug choices in autoimmune hepatitis: part B-nonsteroids. Expert Rev Gastroenterol Hepatol 2012; 6: 617-35.
96. Morath C, Schwenger V, Beimler J, et al,. Antifibrotic actions of mycophenolic acid. Clin Transpl 2006; 20 (Suppl. 17): 25-9.
97. Opelz G, Vogten AJ, Summerskill WH, et al,. HLA determinants in chronic active liver disease: possible relation of HLA-Dw3 to prognosis. Tissue Antigens 1977; 9: 36-40.
98. Czaja AJ, Strettell MD, Thomson LJ, et al,. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-23.
99. Friedman SL,. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
100. Lee UE, Friedman SL,. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206.
101. Friedman SL,. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
102. Issa R, Zhou X, Constandinou CM, et al,. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795-808.
103. Fox CK, Furtwaengler A, Nepomuceno RR, et al,. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001; 21: 272-9.
104. Canbay A, Taimr P, Torok N, et al,. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83: 655-63.
105. Czock D, Keller F, Rasche FM, et al,. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44: 61-98.
106. Zhan SS, Jiang JX, Wu J, et al,. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435-43.
107. Wheeler MD, Kono H, Yin M, et al,. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med 2001; 31: 1544-9.
108. Sanz-Cameno P, Medina J, Garcia-Buey L, et al,. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol 2002; 37: 723-9.
109. Ronis MJ, Butura A, Sampey BP, et al,. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med 2005; 39: 619-30.
110. Oliveira CP, Stefano JT, de Siqueira ER, et al,. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008; 38: 159-65.
111. Baumgardner JN, Shankar K, Hennings L, et al,. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr 2008; 138: 1872-9.
112. Friedman SL, Arthur MJ,. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989; 84: 1780-5.
113. Bachem MG, Melchior R, Gressner AM,. The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. J Clin Chem Clin Biochem 1989; 27: 555-65.
114. Czaja MJ, Weiner FR, Flanders KC, et al,. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 1989; 108: 2477-82.
115. Hayashi H, Sakai T,. Biological significance of local TGF-beta activation in liver diseases. Front Physiol 2012; 3: 12.
116. Bataller R, Gines P, Nicolas JM, et al,. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
117. Bataller R, Sancho-Bru P, Gines P, et al,. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117-25.
118. Tharaux PL, Chatziantoniou C, Fakhouri F, et al,. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000; 36: 330-6.
119. Marra F, Efsen E, Romanelli RG, et al,. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-78.
120. Mann J, Chu DC, Maxwell A, et al,. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138: 705-14.
121. Yu J, Zhang S, Chu ES, et al,. Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int J Biochem Cell Biol 2010; 42: 948-57.
122. Hsu WH, Lee BH, Hsu YW, et al,. Peroxisome proliferator-activated receptor-gamma activators monascin and rosiglitazone attenuate carboxymethyllysine-induced fibrosis in hepatic stellate cells through regulating the oxidative stress pathway but independent of the receptor for advanced glycation end products signaling. J Agri Food Chem 2013; 61: 6873-9.
123. Kisseleva T, Cong M, Paik Y, et al,. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 2012; 109: 9448-53.
124. Hezode C, Roudot-Thoraval F, Nguyen S, et al,. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71.
125. Julien B, Grenard P, Teixeira-Clerc F, et al,. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-55.
126. Kang KW, Kim YG, Cho MK, et al,. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. Faseb J 2002; 16: 1988-90.
127. Kim SG, Kim YM, Choi JY, et al,. Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial. J Pharm Pharmacol 2011; 63: 627-35.
128. Ratziu V, Giral P, Jacqueminet S, et al,. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
129. Nan YM, Fu N, Wu WJ, et al,. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 2009; 44: 358-65.
130. Ratziu V, Charlotte F, Bernhardt C, et al,. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-53.
131. Gupte AA, Liu JZ, Ren Y, et al,. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 2010; 52: 2001-11.
132. Ackerman Z, Oron-Herman M, Pappo O, et al,. Hepatic effects of rosiglitazone in rats with the metabolic syndrome. Basic Clin Pharmacol Toxicol 2010; 107: 663-8.
133. Sanyal AJ, Chalasani N, Kowdley KV, et al,. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
134. Boettcher E, Csako G, Pucino F, et al,. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35: 66-75.
135. Colmenero J, Bataller R, Sancho-Bru P, et al,. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 2009; 297: G726-34.
136. Pandey R, Hegde VL, Singh NP, et al,. Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis. Vitam Horm 2009; 81: 487-504.
137. Gelfand EV, Cannon CP,. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 2006; 15: 307-15.
138. Nissen SE, Wolski K,. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
139. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al,. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-8.
140. Desmouliere A, Darby I, Costa AM, et al,. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab Invest 1997; 76: 765-78.
141. Arthur MJ, Fibrogenesis II,. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G245-9.
142. Benyon RC, Iredale JP, Goddard S, et al,. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-31.
143. Murphy FR, Issa R, Zhou X, et al,. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002; 277: 11069-76.
144. Iredale JP, Benyon RC, Pickering J, et al,. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-49.
145. Issa R, Williams E, Trim N, et al,. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548-57.
146. Barry-Hamilton V, Spangler R, Marshall D, et al,. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-17.
147. Sakaida I, Terai S, Yamamoto N, et al,. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004; 40: 1304-11.
148. Sugino H, Kumagai N, Watanabe S, et al,. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2008; 23: 1909-16.
149. Czaja AJ, Carpenter HA,. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol 2007; 5: 898-907.
150. Rockey DC, Caldwell SH, Goodman ZD, et al,. Liver biopsy. Hepatology 2009; 49: 1017-44.
151. Scheuer PJ,. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003; 38: 1356-8.
152. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsies in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
153. Westin J, Lagging LM, Wejstal R, et al,. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183-7.
154. Brunt EM,. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241-6.
155. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
156. Poynard T, Morra R, Ingiliz P, et al,. Biomarkers of liver fibrosis. Adv Clin Chem 2008; 46: 131-60.
157. Poynard T, Ngo Y, Perazzo H, et al,. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 2011; 7: 445-54.
158. Ngo Y, Munteanu M, Messous D, et al,. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96.
159. Parkes J, Roderick P, Harris S, et al,. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.
160. Nunes D, Fleming C, Offner G, et al,. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-53.
161. Vergniol J, Foucher J, Terrebonne E, et al,. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9.
162. Naveau S, Gaude G, Asnacios A, et al,. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105.
163. Angulo P, Bugianesi E, Bjornsson ES, et al,. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-9.
164. Poynard T, Imbert-Bismut F, Ratziu V, et al,. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 128-33.
165. Poynard T, Ngo Y, Munteanu M, et al,. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr Hepat Rep 2011; 10: 87-97.
166. Poynard T, de Ledinghen V, Zarski JP, et al,. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol 2012; 56: 541-8.
167. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
168. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
169. Shah AG, Lydecker A, Murray K, et al,. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
170. Rosenberg WM, Voelker M, Thiel R, et al,. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13.
171. Parkes J, Guha IN, Roderick P, et al,. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011; 18: 23-31.
172. Guha IN, Parkes J, Roderick P, et al,. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.
173. Brunt EM, Janney CG, Di Bisceglie AM, et al,. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
174. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
175. Nobili V, Parkes J, Bottazzo G, et al,. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136: 160-7.
176. Mayo MJ, Parkes J, Adams-Huet B, et al,. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-57.
177. Colli A, Fraquelli M, Andreoletti M, et al,. Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases. Radiology 2003; 227: 89-94.
178. Friedrich-Rust M, Ong MF, Martens S, et al,. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
179. Friedrich-Rust M, Ong MF, Herrmann E, et al,. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007; 188: 758-64.
180. Yin M, Talwalkar JA, Glaser KJ, et al,. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: e2.
181. Yin M, Woollard J, Wang X, et al,. Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastography. Magn Reson Med 2007; 58: 346-53.
182. Talwalkar JA, Yin M, Fidler JL, et al,. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008; 47: 332-42.
183. Talwalkar JA, Yin M, Venkatesh S, et al,. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. Am J Roentgenol 2009; 193: 122-7.
184. Kim BH, Lee JM, Lee YJ, et al,. MR elastography for noninvasive
185. Xanthakos SA, Podberesky DJ, Serai SD, et al,. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr 2013; doi: 10.1016/j.jpeds.2013.07.050 [Epub ahead of print].
186. Friedrich-Rust M, Wunder K, Kriener S, et al,. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252: 595-604.
187. Piscaglia F, Marinelli S, Bota S, et al,. The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives. Eur J Radiol 2013; doi: 10.1016/j.ejrad.2013.06.009 [Epub ahead of print].
188. Sandrin L, Fourquet B, Hasquenoph JM, et al,. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
189. Boursier J, Zarski JP, de Ledinghen V, et al,. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57: 1182-91.
190. Castera L, Vergniol J, Foucher J, et al,. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
191. Crespo G, Fernandez-Varo G, Marino Z, et al,. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012; 57: 281-7.
192. Tatsumi C, Kudo M, Ueshima K, et al,. Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography. Intervirology 2008; 51 (Suppl. 1): 27-33.
193. Poynard T, de Ledinghen V, Zarski JP, et al,. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clin Res Hepatol Gastroenterol 2011; 35: 720-30.
194. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al,. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214-20.
195. Stebbing J, Farouk L, Panos G, et al,. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-9.
196. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al,. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.
197. Kim SU, Kim do Y, Park JY, et al,. How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol 2010; 44: 66-71.
198. Chan HL, Wong GL, Choi PC, et al,. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
199. Sagir A, Erhardt A, Schmitt M, et al,. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47: 592-5.
200. Millonig G, Reimann FM, Friedrich S, et al,. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48: 1718-23.
201. Millonig G, Friedrich S, Adolf S, et al,. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010; 52: 206-10.
202. Roulot D, Czernichow S, Le Clesiau H, et al,. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-13.
203. Castera L, Foucher J, Bernard PH, et al,. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35.
204. Myers RP, Pomier-Layrargues G, Kirsch R, et al,. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
205. Colombo S, Buonocore M, Del Poggio A, et al,. Head-to-head comparison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. J Gastroenterol 2012; 47: 461-9.
206. Chung JH, Ahn HS, Kim SG, et al,. The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis. Clin Mol Hepatol 2013; 19: 156-64.
207. D'Onofrio M, Crosara S, De Robertis R, et al,. Acoustic radiation force impulse of the liver. World J Gastroenterol 2013; 19: 4841-9.
208. Piscaglia F, Salvatore V, Di Donato R, et al,. Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography. Ultraschall Med 2011; 32: 167-75.
209. Sporea I, Sirli R, Bota S, et al,. Comparative study concerning the value of acoustic radiation force impulse elastography (ARFI) in comparison with transient elastography (TE) for the assessment of liver fibrosis in patients with chronic hepatitis B and C. Ultrasound Med Biol 2012; 38: 1310-6.
210. Bota S, Herkner H, Sporea I, et al,. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013; 33: 1138-47.
211. Sporea I, Sirli R, Popescu A, et al,. Acoustic Radiation Force Impulse (ARFI)-a new modality for the evaluation of liver fibrosis. Med Ultrason 2010; 12: 26-31.
212. Ebinuma H, Saito H, Komuta M, et al,. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan((R)). J Gastroenterol 2011; 46: 1238-48.
213. Haque M, Robinson C, Owen D, et al,. Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: a pilot study. Ann Hepatol 2010; 9: 289-93.
214. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
215. Yap WW, Kirke R, Yoshida EM, et al,. Non-invasive assessment of liver fibrosis using ARFI with pathological correlation, a prospective study. Ann Hepatol 2013; 12: 608-15.
216. Ye XP, Ran HT, Cheng J, et al,. Liver and spleen stiffness measured by acoustic radiation force impulse elastography for noninvasive assessment of liver fibrosis and esophageal varices in patients with chronic hepatitis B. J Ultrasound Med 2012; 31: 1245-53.
217. Morishita N, Hiramatsu N, Oze T, et al,. Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis. J Gastroenterol 2013 [Epub ahead of print].
218. Motosugi U, Ichikawa T, Niitsuma Y, et al,. Acoustic radiation force impulse elastography of the liver: can fat deposition in the liver affect the measurement of liver stiffness? Jpn J Radiol 2011; 29: 639-43.
219. Chen SH, Li YF, Lai HC, et al,. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. BMC Gastroenterol 2012; 12: 105.
220. Yoon KT, Lim SM, Park JY, et al,. Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci 2012; 57: 1682-91.
221. Bota S, Sporea I, Sirli R, et al,. Factors which influence the accuracy of acoustic radiation force impulse (ARFI) elastography for the diagnosis of liver fibrosis in patients with chronic hepatitis C. Ultrasound Med Biol 2013; 39: 407-12.
222. Bota S, Sporea I, Peck-Radosavljevic M, et al,. The influence of aminotransferase levels on liver stiffness assessed by acoustic radiation force impulse elastography: a retrospective multicentre study. Dig Liver Dis 2013; 45: 762-8.
223. Karlas TF, Pfrepper C, Rosendahl J, et al,. Acoustic radiation force impulse (ARFI) elastography in acute liver failure: necrosis mimics cirrhosis. Z Gastroenterol 2011; 49: 443-8.
224. Cassinotto C, Lapuyade B, Ait-Ali A, et al,. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography-comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology 2013; 269: 283-92.
225. Righi S, Fiorini E, De Molo C, et al,. ARFI elastography in patients with chronic autoimmune liver diseases: a preliminary study. J Ultrasound 2012; 15: 226-31.
226. Ahmad A, Ahmad R,. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol 2012; 18: 155-67.
227. Czaja AJ,. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007; 1: 113-28.
228. Czaja AJ,. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci 2010; 55: 2712-26.
229. Boetticher NC, Peine CJ, Kwo P, et al,. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-60.
230. Ghabril M, Bonkovsky HL, Kum C, et al,. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: e3.
231. Akriviadis E, Botla R, Briggs W, et al,. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48.
232. Germano V, Picchianti Diamanti A, Baccano G, et al,. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-20.
233. Tobon GJ, Canas C, Jaller JJ, et al,. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578-81.
234. Fairhurst DA, Sheehan-Dare R,. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol 2009; 34: 421-2.
235. Wang Y, Gao J, Zhang D, et al,. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-44.
236. Liu Y, Wang Z, Kwong SQ, et al,. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011; 55: 612-25.
237. Galli A, Crabb DW, Ceni E, et al,. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-40.
238. McHutchison J, Goodman Z, Patel K, et al,. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 2010; 138: 1365-73.
239. Hiatt WR, Kaul S, Smith RJ,. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med 2013; 369: 1285-7.
240. Kawada N, Seki S, Inoue M, et al,. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998; 27: 1265-74.
241. Majano PL, Medina J, Zubia I, et al,. N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J Hepatol 2004; 40: 632-7.
242. Mato JM, Camara J, Fernandez de Paz J, et al,. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-9.
243. Karaa A, Thompson KJ, McKillop IH, et al,. S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock 2008; 30: 197-205.
244. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, et al,. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002; 76: 1177S-82S.
245. Harrison SA, Torgerson S, Hayashi P, et al,. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-90.
246. Vidali M, Tripodi MF, Ivaldi A, et al,. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008; 48: 399-406.
247. Vos TA, Van Goor H, Tuyt L, et al,. Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is dependent on the cellular glutathione status. Hepatology 1999; 29: 421-6.
248. Zafarullah M, Li WQ, Sylvester J, et al,. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 6-20.
249. Vercelino R, Crespo I, de Souza GF, et al,. S-nitroso-N-acetylcysteine attenuates liver fibrosis in cirrhotic rats. J Mol Med 2010; 88: 401-11.
250. Majano PL, Garcia-Monzon C, Garcia-Trevijano ER, et al,. S-Adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes. J Hepatol 2001; 35: 692-9.
251. Feld JJ, Modi AA, El-Diwany R, et al,. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology 2011; 140: 830-9.
252. Parola M, Leonarduzzi G, Biasi F, et al,. Vitamin E dietary supplemen-tation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology 1992; 16: 1014-21.
253. Parola M, Muraca R, Dianzani I, et al,. Vitamin E dietary supplemen-tation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992; 308: 267-70.
254. Hasegawa T, Yoneda M, Nakamura K, et al,. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
255. Moreno-Otero R,. May oxidative stress contribute to autoimmune hepatitis pathogenesis, and can antioxidants be of value as adjuvant therapy for refractory patients? Dig Dis Sci 2013; 58: 1440-1.
256. Corey KE, Shah N, Misdraji J, et al,. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009; 29: 748-53.
257. Cholongitas E, Vibhakorn S, Lodato F, et al,. Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation. Liver Int 2010; 30: 334-5.
258. Abu Dayyeh BK, Yang M, Dienstag JL, et al,. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci 2011; 56: 564-8.
259. Verma S, Gunuwan B, Mendler M, et al,. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-6.
260. Miyake Y, Iwasaki Y, Terada R, et al,. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-7.
261. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-12.
262. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-45.
263. Berzigotti A, Ashkenazi E, Reverter E, et al,. Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers 2011; 31: 129-38.
264. Czaja AJ,. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part- I. Inflamm Allergy Drug Targets 2012; 11: 337-50.
265. Czaja AJ,. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol 2012; 26: 615-20.
266. Czaja AJ, Carpenter HA,. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.
267. Czaja AJ,. Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol 2013; 27: 531-9.
268. Czaja AJ,. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis 2009; 29: 315-30.
269. Czaja AJ, Carpenter HA, Santrach PJ, et al,. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502-7.
270. Czaja AJ,. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008; 25: 219-39.
271. Zolfino T, Heneghan MA, Norris S, et al,. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713-7.
272. Czaja AJ,. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol 2013; 7: 365-85.